Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2019-10-02 | Former CEO experience; Founder of the ICS business; Extensive financial services and technology industry experience and knowledge. |
| 2020-10-06 | Mr. Daly served as our CEO from 2007 to 2019... Extensive financial services and technology industry experience and knowledge. |
| 2021-10-05 | Specific Experience, Qualifications, Attributes or Skills: Former CEO experience brings unique perspective and insights into the Company, including its businesses, relationships, competitive, financial and regulatory positioning, senior leadership and strategic opportunities and challenges; Founder of the ICS business; Extensive financial services and technology industry experience and knowledge; Financial expertise and financial literacy; Sales and marketing experience; International business experience; Corporate governance experience; Legal/regulatory/government experience. |
| 2022-09-27 | Specific Experience, Qualifications, Attributes or Skills: Former CEO experience; Extensive financial services and technology industry experience and knowledge |
| 2023-09-27 | CEO of Broadridge Financial Solutions, Inc. from 2007-2019; Group President of the Brokerage Services Group of ADP. |
| 2024-10-02 | CEO of Broadridge Financial Solutions, Inc. from 2007-2019; Group President of the Brokerage Services Group of Automatic Data Processing, Inc. (ADP). |
| Filing Date | Source Excerpt |
|---|---|
| 2016-04-29 | Mr. Daly currently serves as President and CEO of Neuralstem, Inc., a biopharmaceutical company... Mr. Daly received his Bachelor of Science in Microbiology from the University of Notre Dame and his MBA from the Kellogg School of Management. |
| 2017-04-14 | Richard J. Daly joined our Board of Directors in February 2015. Mr. Daly currently serves as Chairman and CEO of Neuralstem, Inc. (NASDAQ: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neuronal stem cell technology. Until October 2014, Mr. Daly served as President of AstraZeneca US Diabetes, where he led all commercial and medical plans and objectives for a $1.2 billion, 3,000-employee division, including the successful launch of an orphan/rare disorder drug, Myalept, for Lipodystrophy. From 2011 through 2013, Mr. Daly served as a Co-Founder of and an investor in Sagepath Partners, a company providing the pharmaceutical industry with outsourced commercial services. From 2008 to 2011, Mr. Daly was employed by Takeda N.A., the North American subsidiary of Takeda Pharmaceuticals, serving first as Vice President, Integration, leading a 6,500 person commercial/R&D merger between TAP Pharmaceuticals and Takeda N.A., and then as Executive Vice President of Takeda N.A., with commercial responsibility for all businesses in the Americas. From 2006 to 2008, Mr. Daly served as the Vice President, Commercial Strategy for TAP Pharmaceuticals, a joint venture between Takeda Pharmaceuticals and Abbott Labs. In 1998, Mr. Daly was a founding member of the leadership team of Takeda Pharmaceuticals N.A., serving initially as the Senior Director of Marketing. Between 1998 and 2006, Mr. Daly took on roles of increasing responsibility culminating in his appointment as Senior Vice President, Marketing (2001-2006). Mr. Daly currently serves on the Board of Directors of Synergy Pharmaceuticals, Inc., where he serves on the Compensation, Commercial and Nomination/Governance Committees of the Board of Directors (Chair of the Nomination/Governance Committee). Mr. Daly received his Bachelor of Science in Microbiology from the University of Notre Dame in 1983 and his MBA from the Kellogg School of Management, Northwestern University in 1998. |
| 2018-04-17 | Mr. Daly currently serves as Chairman and CEO of Neuralstem, Inc., a biopharmaceutical company focused on the development of central nervous system therapies based on its neuronal stem cell technology. ... Mr. Daly received his Bachelor of Science in Microbiology from the University of Notre Dame and his MBA from the Kellogg School of Management. |
| 2019-04-18 | Mr. Daly currently serves as Chief Operating Officer of BeyondSpring Pharma, a pre-commercial company focused on cancer. From 2016 until mid-2018, Mr. Daly served as Chairman and CEO of Neuralstem, Inc., a biopharmaceutical company focused on the development of central nervous system therapies. |
| 2020-07-07 | The Board believes that the characteristics that qualify Mr. Daly to be a director of our company include his significant pharmaceutical industry experience and his experience in launching and managing sales of numerous pharmaceutical products. |
| 2022-08-05 | Mr. Daly currently serves as President of CARsgen Therapeutics Corporation, an emerging oncology company focused on developing CAR-T therapies for both liquid and solid tumors. From July 2018 through January 2022, Mr. Daly served as Chief Operating Officer of BeyondSpring Pharmaceuticals, a pre-commercial biotech company focused on oncology with assets in late Phase 3 clinical trials. |
| 2023-07-12 | Mr. Daly currently serves as President of CARsgen Therapeutics Corporation, an emerging oncology company focused on developing CAR-T therapies. He received his Bachelor of Science in Microbiology and his MBA. The Board believes that the characteristics that qualify Mr. Daly to be a director include his significant pharmaceutical industry experience and his experience in launching and managing sales of pharmaceutical products. |
| 2024-04-10 | Mr. Daly served as President of CARsgen Therapeutics Corporation, an emerging oncology company focused on developing CAR-T therapies. He has held leadership roles in biotech and pharmaceutical companies and holds a Bachelor of Science in Microbiology and an MBA, but no software-related qualifications are mentioned. |
| Filing Date | Source Excerpt |
|---|---|
| 2016-04-28 | Mr. Daly holds a BS in Microbiology from The University of Notre Dame and an MBA from Northwestern University's Kellogg Graduate School of Management. In evaluating Mr. Daly’s specific experience, qualifications, attributes and skills in connection with his appointment to our board, we took into account his prior work with both public and private organizations, including his experience in building biopharmaceutical organizations, his strong business development background and his past experience and relationships in the biopharma and biotech fields. |
| 2017-05-01 | Mr. Daly holds a BS in Microbiology from The University of Notre Dame and an MBA from Northwestern University's Kellogg Graduate School of Management. |
| 2018-04-25 | Mr. Daly holds a BS in Microbiology from The University of Notre Dame and an MBA from Northwestern University's Kellogg Graduate School of Management. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-04-25